Abstract:
Objective The objective of this study was to observe the clinical effects of early treatment with Jin-long capsules combined with transarterial chemoembolization(TACE) in primary liver cancer.
Methods Seventy patients with primary liver cancer were randomly divided into two groups, namely, the contrast group(administered with TACE only) and the treatment group(given TACE and Jin-long capsules).The contrast group received TACE treatment with E-ADM + 5-Fu + DDP once.By contrast, the treatment group was given 1 g of Jin-long capsules initially and thrice a day before the 7-day TACE regimen began, which lasted for 5 weeks(continuously).
Results The two groups significantly differed in their tumor lesion size, liver function index, TCM symptomatic score, KPS score, and cytokine switching of Th1 and Th2(P < 0.05).
Conclusions Clinical research shows that early intervention with Jin-long capsules for primary liver cancer can improve the efficiency of anticancer therapy, minimize adverse reactions, as well as protect the liver, improve the quality of life, and enhance the immune function of patients.Jin-long capsules have no adverse reactions, such as bleeding and coagulation disorders.